03.10.13
Brachytherapy unit opens at The Christie
A new £3.8m brachytherapy and molecular radiotherapy unit is now open at The Christie, to offer patients improved treatment and a better environment.
Brachytherapy is associated with fewer side effects as lower doses of radiotherapy are given to healthy tissues surrounding a tumour. The unit will also deliver molecular radiotherapy, where patients receive radioactive pharmaceuticals as a drink, capsules or injection.
Chief executive at The Christie, Caroline Shaw, said: “Through providing these treatments in the highest quality environment and integrating these services we will be able to significantly improve the patient experience. It will also enable us to cope with any future increased demand and improve the quality of care for patients, using cutting edge techniques.”
Project lead for the new unit and consultant clinical oncologist Dr Susan Davidson, said: “Patients undergoing molecular radiotherapy often have to spend up to five days in isolation and facilities in this new unit are significantly improved and more efficient than before. There is growing demand for these forms of treatments and this new unit will also allow us to treat more patients than before.”
Tell us what you think – have your say below, or email us directly at [email protected]